Goldman Sachs·2026-10-13CompanyBuy$450 → $475▲Amgen Inc. (AMGN.US) Constructive into second Phase 3 Sj-gren's disease data
BofA Securities·2026-10-12CompanyUnderperform$317 → $328▲Amgen Inc. (AMGN.US) 3Q26: Commercial momentum; pipeline execution remains key; Reit. Underperform
Morgan Stanley·2026-09-22CompanyEqual-weight$362Amgen Inc. (AMGN.US) Dazo succeeds in first of two Ph3 Sjogren's trials
HSBC·2026-09-16SectorBuy → Hold▼$445 → $425▼To infinity and beyond......or not? Evaluating the catalyst path to 2027AbbVie·Top pickJohnson & Johnson·Top pickMerck & Co·Top pickBayer·Top pickSanofi·Top pickEli Lilly·Avoid
Goldman Sachs·2026-10-27SectorBuy$481Global Healthcare: Pharmaceuticals: Key takeaways from our lung cancer KOL event at ESMO
Bernstein·2026-10-25SectorMarket-PerformUS Biopharmaceuticals: US Biopharma @ ESMO-the most impactful data presented thus far (& implications for our coverage)
J.P. Morgan·2026-10-23SectorCardiology Expert Call: Key Takeaways from the Expert Call on the Evolving Cardiology Landscape
Goldman Sachs·2026-10-15SectorAmericas Healthcare: Biotechnology: 3Q earnings preview: Navigating macro and idiosyncratic crosscurrents
Bernstein·2026-08-20SectorMarket-Perform$345US Biopharma: As MRNA leads pharma & biotech (much) higher- what's real & what's hype?